Dr. Sheriah de Paz-Silava, Assistant Professor, College of Public Health, University of the Philippines Manila
The technology aims to provide an additional treatment to Human Immunodeficiency Virus (HIV). It has the strong potential to be the first herbal medicine to target Type 1 HIV which is the most common type.
- Plant or origin (NP) widely available locally
- Solid in vitro tests data
- In vitro tests in HIV latently infected cells showed that NP can slow down virus production to almost zero levels at a concentration not toxic to cells
- NP possesses significant effects on a living matter
- Potential source of lead compounds that can be later purified, identified, and synthesized
MARKET APPLICATION AND COMMERCIAL OPPORTUNITIES
Emerging drug resistance to HIV antiretroviral therapy (ART) poses great challenges in the control of the HIV/AIDS pandemic. In the Philippines, the incidence is 42 times higher than in the past decade, with up to 10% of patients failing to achieve viral suppression after only one year of treatment. Access to medications are also limited to only 100 treatment hubs in some major cities in the archipelago. Moreover, there is still no drug that targets the biggest obstacle for cure- the presence of latently infected reservoirs.
Interviews with relevant institutions have been conducted and has shown an encouraging commercialization pathway.
Our findings warrant further investigations to develop NP into a potential HIV drug that targets HIV latently infected cells with a mechanism of action that has never been used in the clinical setting.
INTELLECTUAL PROPERTY STATUS
Invention Patent has been filed in the Philippines.
TYPE OF COOPERATION
Research Collaboration with pharmaceutical companies/laboratories for the preclinical and clinical trials.